belrestotug
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Oct 4, 2023 (NCT06062420)
Timeline
Indications
Mechanism of action
inhibitor - TIGIT
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06472076 | Phase 3 | Jun 10, 2024 | GlaxoSmithKline, iTeos Therapeutics |
| NCT06062420 | Phase 2 | Oct 4, 2023 | GlaxoSmithKline, iTeos Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 2 | 2 | 2 | 2023 |
| iTeos Therapeutics | For profit | 2 | 0 | 2 | 2023 |
2 organizations
Page 1 / 1